In June 2016, IMUGEN, Inc. wasa acquired in an all cash transaction by Oxford Immunotec Global PLC (NASDAQ: OXFD). Imugens Inc had provided specialized testing for vector (tick) borne diseases such as Lyme disease, Babesiosis, and Ehrlichiosis. Diagnosis of these uncommon infections requires clinical experience and excellent laboratory support. Complications may be severe if there is a misdiagnosis. The incidence of these tick-borne infections is on the rise. Accurate diagnosis may often be perplexing due to complex clinical presentations and limitations of the commonly available laboratory kits. IMUGEN had worked closely with leading clinical researchers developing unique specialized assays which provide reliable laboratory diagnosis of tick borne diseases. The firm's numerous publications reflected the clinical validity and sensitivity of their test procedures. In the complicated environment of current laboratory testing, IMUGEN was chosen to provide primary and reference serologic testing for hospitals and clinics in the most endemic regions of the Northeast. The expanding and unmet needs in areas of blood borne infections as well as rheumatologic disorders and auto-immune diseases, led IMUGEN to expand its laboratory services to encompass these specialty areas eith their expertise in developing appropriate and clinically useful methodologies providing reliable answers to complex diagnostic questions.
